Evidence map›Paper›PMID 35328730›Full record

ReviewInternational journal of molecular sciences2022

miRNAs in Cardiac Myxoma: New Pathologic Findings for Potential Therapeutic Opportunities.

Antonio Nenna, Francesco Loreni, Omar Giacinto, Camilla Chello, Pierluigi Nappi, Massimo Chello, Francesco Nappi

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Cardiac myxoma: a comprehensive review.Journal of cardiothoracic surgery · 2025
    Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Antonio NennaCardiac Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.ORCID 0000-0002-4069-6781
Francesco LoreniCardiac Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.ORCID 0000-0002-2577-1843
Omar GiacintoCardiac Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.
Camilla ChelloIntegrated Biomedical Science and Bioethics, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.
Pierluigi NappiCardiology, Università degli Studi di Messina, 98122 Messina, Italy.
Massimo ChelloCardiac Surgery, Università Campus Bio-Medico di Roma, 00128 Rome, Italy.ORCID 0000-0001-8178-7068
Francesco NappiCardiac Surgery, Centre Cardiologique du Nord de Saint Denis, 93200 Paris, France.ORCID 0000-0002-9705-5360
Università Campus Bio-Medico · ITCentre Cardiologique du Nord · FRUniversity of Messina · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MicroRNAs (miRNAs) regulate gene expression at the post-transcriptional level, contributing to all major cellular processes. The importance of miRNAs in cardiac development, heart function, and valvular heart disease has been shown in recent years, and aberrant expression of miRNA has been reported in various malignancies, such as gastric cancer and breast cancer. Different from other fields of investigation, the role of miRNAs in cardiac tumors still remains difficult to interpret due to the scarcity publications and a lack of narrative focus on this topic. In this article, we summarize the available evidence on miRNAs and cardiac myxomas and propose new pathways for future research. miRNAs play a part in modifying the expression of cardiac transcription factors (miR-335-5p), increasing cell cycle trigger factors (miR-126-3p), interfering with ceramide synthesis (miR-320a), inducing apoptosis (miR-634 and miR-122), suppressing production of interleukins (miR-217), and reducing cell proliferation (miR-218). As such, they have complex and interconnected roles. At present, the study of the complete mechanistic control of miRNA remains a crucial issue, as proper understanding of signaling pathways is essential for the forecasting of therapeutic implications. Other types of cardiac tumors still lack adequate investigation with regard to miRNA. Further research should aim at investigating the causal relationship between different miRNAs and cell overgrowth, considering both myxoma and other histological types of cardiac tumors. We hope that this review will help in understanding this fascinating molecular approach.

Indexed as

Heart NeoplasmsMicroRNAsMyxomaStomach NeoplasmsCell ProliferationGene Expression ProfilingHumansMicroRNAsMIRN217 microRNA, humanMIRN218 microRNA, humancardiac surgerycardiac tumorsmiRNAmyxoma

Identifiers

PMID35328730
PMCPMC8954653
OpenAlexW4220915766

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.